News

The acquisition will allow Encore leverage Quintiles’ breadth and depth of capabilities as well as its global scale to speed up Encore’s vision of improving clinical outcomes through

The company secured a sublicense agreement to manufacture, market and distribute the oral spray product under the brand name TapouT XT in 2013 and since such time has

In 2011, both the firms signed a collaboration and license option agreement for several pre-defined pathogens. As part of the 2011 deal, CureVac met all pre-agreed milestones and

NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena’s lead development agent in multiple ongoing and planned clinical trials. Once issued, the patent

Cortex is developing dronabinol (D9-tetrahydrocannabinol), a cannabinoid, for the treatment of obstructive sleep apnea (OSA), the most common form of sleep apnea. Cortex previously conducted a 21 day,

The combination creates one of the world’s fastest-growing specialty pharmaceutical companies, with annual revenues of more than $15 billion anticipated for 2015. In conjunction with the close of

In the study a statistically significant greater proportion of rifaximin treated subjects (as compared to placebo) responded to repeat treatment as assessed by the composite primary endpoint of

Founders Fund and Max Levchin, a PayPal co-founder, led this latest financing along with investment from Schooner Capital. The company also announced the release of its first product:

Lemtrada, a monoclonal antibody that selectively targets CD52, has been approved by ANMAT to treat adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by